Skip to main content
. 2023 Aug 21;3(6):600–619. doi: 10.1021/acsmaterialsau.3c00032

Table 2. Toxicity of LNP-Based Marketed Drugs.

Marketed formulation active drug toxicity symptoms ref
Doxil doxorubicin hand-foot syndrome, stomatitis, skin toxicity (facial swelling, itching), hypersensitivity reactions, mild myelosuppression and alopecia, dyspnea (200202)
Myocet doxorubicin neutropenia, mild cardiotoxic (203)
Abelcet, Amphotec, AmBisome amphotericin B nephrotoxicity, hypersensitivity reactions such as rash, flushing, facial edema, bronchospasm, persistent fever and rigors, hypokalemia (204206)
Linhaliq/Pulmaquin ciprofloxacin dyspnea, bronchospasm, hemoptysis, cough, taste disorders. (207)
Daunoxome daunorubicin hematological toxicity such as neutropenia, back pain (208, 209)
Visudyne verteporfin back pain, chest pain, dyspnea, dizziness, rash (210)
Arikace amikacin ototoxicity including deafness, dizziness, vertigo, dysphonia, pneumonitis, laryngitis (211, 212)
Ambraxane paclitaxel neutropenia, hypersensitivity reactions, neuropathy, severe myelosuppression (213)